![]() | ![]() |
Formats:
|
||||||||||||||||||||||||
Copyright This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original DOI. Research Deducing in Vivo Toxicity of Combustion-Derived Nanoparticles from a Cell-Free Oxidative Potency Assay and Metabolic Activation of Organic Compounds Helmholtz Zentrum München, German Research Center for Environmental Health, Institute of Inhalation Biology, Neuherberg/Munich, Germany Address correspondence to T. Stoeger, Ingolstaedter Landstrasse 1, D-85758 Neuherberg/Munich, Germany. Telephone: 49-89-3187-3104. Fax: 49-89-3187-2400. E-mail: tobias.stoeger/at/helm-holtz-muenchen.de The authors declare they have no competing financial interests. Received February 14, 2008; Accepted August 22, 2008. This article has been cited by other articles in PMC.Abstract Background The inhalation of combustion-derived nanoparticles (CDNPs) is believed to cause an oxidative stress response, which in turn may lead to pulmonary or even systemic inflammation. Objective and Methods In this study we assessed whether the in vivo inflammatory response—which is generally referred to as particle toxicity—of mice to CDNPs can be predicted in vitro by a cell-free ascorbate test for the surface reactivity or, more precisely, oxidative potency (OxPot) of particles. Results For six types of CDNPs with widely varying particle diameter (10–50 nm), organic content (OC; 1–20%), and specific Brunauer, Emmett, and Teller (BET) surface area (43–800 m2/g), OxPot correlated strongly with the in vivo inflammatory response (pulmonary polymorphonuclear neutrophil influx 24 hr after intratracheal particle instillation). However, for CDNPs with high organic content, OxPot could not explain the observed inflammatory response, possibly due to shielding of the OxPot of the carbon core of CDNPs by an organic coating. On the other hand, a pathway-specific gene expression screen indicated that, for particles rich in polycyclic aromatic hydrocarbon (PAHs), cytochrome P450 1A1 (CYP1A1) enzyme-mediated biotransformation of bio-available organics may generate oxidative stress and thus enhance the in vivo inflammatory response. Conclusion The compensatory nature of both effects (shielding of carbon core and biotransformation of PAHs) results in a good correlation between inflammatory response and BET surface area for all CDNPs. Hence, the in vivo inflammatory response can either be predicted by BET surface area or by a simple quantitative model, based on in vitro OxPot and Cyp1a1 induction. Keywords: air pollution, BET, biotransformation, carbonaceous particles, Cyp1a1, dose response, nanoparticles, nanotoxicity, organic compounds, oxidative stress, particle toxicity, soot particles, specific surface area, surface toxicity, ultrafine particles Epidemiologic and clinical studies have linked elevated concentrations of ambient particulate matter (PM) to adverse health effects throughout the industrialized world (Kleeberger 2005). In urban environments, combustion-derived nanoparticles (CDNPs) such as soot particles dominate PM number concentrations and contribute significantly to the total PM surface area. Typically, these particles consist of a carbon core coated with potentially toxic air pollutants consisting of hundreds of organic chemicals and many transition metals (Kreyling et al. 2004; Oberdörster et al. 2005). At present, it is commonly hypothesized that the toxicity of ultrafine soot particles is largely driven by adsorbed redox-active components [e.g., poly-aromatic hydrocarbons (PAHs)], which participate in redox-cycling reactions generating reactive oxygen species (ROS). These ROS can cause oxidative stress responses that may result in pulmonary or even systemic inflammation (Li et al. 2003a; Risom et al. 2005). Ultimately, these processes may promote the progression of atherosclerosis and precipitate acute cardiovascular responses ranging from increased blood pressure to myocardial infarction (Delfino et al. 2005). To counteract the adverse effects of oxidative stress generated by redox cycling and electrophilic compounds, nature “developed” an elaborate defense system to maintain redox homeostasis. This system includes a series of anti-oxidant enzymes, in particular, the so-called phase II xenobiotic metabolism enzymes that metabolize redox-cycling chemicals, eliminate excessive ROS, and protect cells against the damaging effects of electrophiles and oxidants (Winyard et al. 2005). A disturbance of the cellular redox equilibrium and related disproportionate oxidative stress is well known to trigger multiple stress kinase pathways and redox-sensitive transcription factors, such as nuclear factor-erythroid 2-p45–related factor 2 (Nrf2), which activates the expression of antioxidant and cytoprotective genes, as well as the nuclear localization of nuclear factor kappa B (NF-kB) and activator protein-1 (AP-1), which play key roles in gene promotion for inflammatory mediators (Cho et al. 2006; Rahman et al. 2006). Identification of the particle properties that are most relevant for promoting adverse health effects is crucial not only for our mechanistic understanding but also for the implementation of strategies for improving air quality. For different kinds of particles with low toxicity and solubility, particle surface area has shown to be a useful dose metric for the characterization of particle-induced neutrophil response in the exposed lung (Oberdörster et al. 2005). Inflammatory effects of diesel exhaust particles (DEP) appear to be driven by particle surface area (Heinrich et al. 1995), although the type of organic (Baeza-Squiban et al. 1999) and metal (Ball et al. 2000) components also appear to play a role in oxidative and proinflammatory effects and subsequent pathogenicity. This is consistent with studies describing different classes of surface toxicity pointing to different pathways of particle-related stress induction (Dick et al. 2003; Donaldson et al. 2005; Duffin et al. 2002; Warheit et al. 2006). In a previous study, we found that for six different types of CDNPs, the organic carbon content (OC) had a much weaker impact on the acute inflammatory response in the lungs of mice (24 hr after intratracheal instillation) than did Brunauer, Emmett, and Teller (BET) surface area, with predictive values of 0.0286 versus < 0.0001, respectively (Stoeger et al. 2006). Although BET surface area appears to be the single most relevant parameter for the prediction of particle toxicity, it is likely that other parameters such as the presence of free radicals, particle charge, and the bioavailability of adsorbed components may explain the observed differences in surface toxicity (Stoeger et al. 2006; Wittmaack 2007). The objective of the present study was to assess the possibility of predicting particle toxicity based on the combined information from a cell-free in vitro test for the innate oxidative potency (OxPot) of particles and a gene expression analysis targeting inflammation, stress, and detoxification-related genes. Here we relate the results from both tests to our previously published in vivo data on the acute inflammatory response of mice for six types of CDNPs (Stoeger et al. 2006) and introduce a simple two-parameter model to quantitatively describe the toxicity of CDNPs from the OxPot and bioavailability of organic components. Ultimately, this model may serve as an additional step toward introducing a cell-free test for nanotoxicology that is reliable enough to make animal studies obsolete. Materials and Methods Particles In the present study we used the same six CDNP types as we described previously (Stoeger et al. 2006). Briefly, we purchased DEPs [standard reference material SRM-1650a; National Institute of Standards and Technology (NIST), Gaithersburg, MD, USA] and PrintexG (PtxG) and Printex90 (Ptx90; pigment black; Degussa, Frankfurt, Germany) and generated and filter-sampled SootH (high OC), SootL (low OC), and ultra-fine carbon particles (UfCPs) in our laboratory. We produced SootH and SootL particles by a well-controlled diffusion flame (CAST burner, Matter Engineering AG, Wohlen, Switzerland) with low and high oxygen-to-fuel ratios, respectively, resulting in soot particles with different amounts (and types) of organic compounds (Matuschek et al. 2007). The UfCPs, generated by spark discharge from graphite electrodes (GFG1000, Palas, Karlsruhe, Germany) (Roth et al. 2004), are noncombustion-derived particles with low OC, large specific surface area, and structural and compositional similarities with modern (Euro IV) diesel soot (Su et al. 2004). Table 1 lists the BET surface area [determined using the method described by Brunauer, Emmett, and Teller (1938)] and OC of all six particle types as reported previously (Stoeger et al. 2006) covering a wide range from about 40 to 800 m2/g and from 1% to 20% OC. The (primary) particle diameter of the nanoparticle types ranged from about 10 to 50 nm (Stoeger et al. 2006). For the biological analysis of the CDNPs described below, we used the entire particles rather than solvent extracts.
Determination of the OxPot of the particles In living organisms, vitamin C (l-ascorbate), a highly effective antioxidant, is consumed as it protects the body against oxidative stress. Therefore, we used the depletion of ascorbate in an aqueous particle suspension as a cell-free in vitro test for the OxPot of particles, where the absence of any metabolic activity in a cell-free system guarantees that this test characterizes the particles’ innate (in absence of metabolic activation) OxPot presumably related to the surface reactivity of the particles. For each particle type, we incubated aliquots of 5, 1, and 0.2 μg for 40 min in an aqueous ascorbate solution (100 μL of 100 μM ascorbate in phosphate-buffered saline; this corresponds to 2.5 nmol ascorbate per 25 μL). After removal of the particles by centrifugation (30,000g/15 min/4°C), we quantified the antioxidative capacity of 25 μL of supernatant using the photochemiluminescence (PCL) method (Photochem, Analytik Jena AG, Jena, Germany), in which the fast photochemical excitation of radical formation is combined with sensitive luminometric detection (Popov and Lewin 1999). We performed two measurements for each particle type and concentration (Figure 1
Determination of the inflammatory efficacy of the particles In the present study, we used the in vivo animal exposure data from our previous study (Stoeger et al. 2006). In brief, for each particle type, we determined the response of eight female BALB/cJ mice (21.1 ± 1 g) after intratracheal instillation of 5, 20, or 50 μg CDNPs in 50 μL aqueous suspension or pure water (sham control), except for UfCP, which also included instillations with 0.5 and 2 μg particles. We treated animals humanely and with regard for alleviation of suffering; experimental protocols were reviewed and approved by the Bavarian Animal Research Authority (approval no. 211-2531-108/99). At 24 hr after instillation, we performed broncho-alveolar lavage (BAL) and assessed BAL fluid for polymorphonuclear neutrophils (PMNs) as a measure of the inflammatory cellular response. In the present study, the previously reported absolute numbers of PMNs (Stoeger et al. 2006) were normalized by the number of BAL leukocytes [Supplemental Material, Figure 1 (http://www.ehponline.org/members/2008/11370/suppl.pdf)], thus eliminating some bias due to varying effectiveness of cell retrieval by the lavage procedure (especially for 50 μg PtxG). Using these data, in the present study we defined the (in vivo) inflammatory efficacy (IEf) as the 20% PMN effect level divided by the particle mass causing this effect level (M20%PMN), that is, IEf = 20% PMN/M20%PMN (%PMN/μg). We chose the 20% PMN threshold because it is significantly different from the sham response (~ 2%), it is clearly beneath saturation levels (> 40%), and it is exceeded by all six particle types [See Supplemental Material, Figure 1 (http://www.ehponline.org/members/2008/11370/suppl.pdf)]. We derived the M20%PMN values by interpolation between the two PMN data points bracketing the 20% effect level. Quantification of gene and protein expression For expression analysis, lavaged lungs from the 20 μg exposure were homogenized using the FastPrep FP120 Cell Disruptor (BIO101/Savant Instruments Inc., Holbrook, NY, USA) automat with Lysing Matrix Tube D (MP Biomedicals, Illkirch, France) and subjected to either RNA or protein extraction (four mice per group). RNA isolation from lung homogenates was processed using the RNeasy Kit (Qiagen, Hilden, Germany). For quantitative reverse-transcriptase polymerase chain reaction (PCR), we used 1 μg total DNase I–treated RNA for the first-strand cDNA reaction using hexamer primer (Promega, Mannheim, Germany) and Superscript II reverse transcriptase (Invitrogen, Karlsruhe, Germany). We pooled cDNA samples from each experimental group and quantified transcript levels using Absolute QPCR SYBR Green Mix plus ROX kit (ABgene, Hamburg, Germany) with the ABI Prism 7000 Sequence Detection System (Applied Biosystems, Foster City, CA, USA). We used the comparative CT (threshold cycle) method to calculate the relative abundance of transcript (Applied Biosystems 1997). For normalization, we used 18S RNA [GenBank accession no. NT_039649.7 (National Center for Biotechnology Information 2008)] as the reference gene to derive the fold increase in relation to the sham control group. Details of the primer and sequence specifications are given in Supplemental Material, Table 1 (http://www.ehponline.org/members/2008/11370/suppl.pdf). We performed extraction of cytoplasmic lung protein in RIPA buffer plus Protease Inhibitor Cocktail III (Merck Chemicals, Darmstadt, Germany). We pooled 20 μg of total lung protein from each of the eight experimental groups (six CDNP types and two controls) and separated it by sodium dodecyl sulfate gel electrophoresis using the XCell II Blot Module and NuPage Novex Bis-Tris Gels and blotted to polyvinyl difluoride membranes (Invitrogen). The following primary antibodies were used: rabbit anti-cyclooxygenase-2 (COX2; ab15191; Abcam, Cambridge, UK), rabbit anti-cytochrome P450 1A1 (CYP1A1; sc-20772; Santa Cruz Biotechnology, Heidelberg, Germany), rabbit anti-rat liver glutathione S-transferase α1 (GST-Ya; AB 0009; Gentaur, Aachen, Germany), rabbit anti-heme oxygenase-1 (HO1; SPA 895; Biomol, Hamburg, Germany), rabbit anti-heat shock 70-kDa protein 1B (HSP70; SPA 812, Biomol), goat anti-NAD(P)H dehydrogenase [quinone] 1 (NQO1; IMG-3033, Biomol), and, as loading control, mouse monoclonal anti–β-actin (ACTB), AC-15 (A1978; Sigma-Aldrich, Taufkirchen, Germany). We applied horseradish peroxidase–linked species-specific secondary antibody for primary antibody detection, donkey anti-rabbit IgG (Amersham/GE Healthcare, Buckinghamshire, UK), rabbit anti-goat (Chemicon International, Millipore Corp., Billerica, MA, USA), and sheep anti-mouse (Amersham/GE Healthcare), using the ECT Plus Detection System (Amersham/GE Healthcare). Scanned blots were analyzed using the Syngene software image analysis program (Syngene, Cambridge, UK) with baseline correction setting “rolling disc.” Protein expression derived from quantified densities of respective bands were normalized to ACTB and expressed as fold change relative to sham controls. Statistical analyses All values are reported as the mean ± SE. We used analysis of variance calculated by Statgraphics software (STSC Inc., Rockville, MD, USA) to establish the statistical significance of differences between the experimental groups. We applied the Tukey honestly significant difference procedure to evaluate the significant differences between the exposed animals and the sham control group. We considered differences significant at p < 0.05. Results In vitro OxPot, in vivo IEf, and surface area of the particles As indicated in our previous study (Stoeger et al. 2006), Figure 2A
Gene expression analysis reveals bio-activation of particle-borne organics To identify the reason for the irregular behavior of SootH, in the lungs of mice 24 hr after the instillation of 20 μg of SootH, we analyzed the expression patterns of 50 genes representing different biologic response types, including inflammation, stress response, metal detoxification, and phase I and II detoxification of xenobiotics such as PAHs. Table 2 displays the expression of the 22 most notably regulated genes [see also Supplemental Material, Figure 2 (http://www.ehponline.org/members/2008/11370/suppl.pdf)] in terms of fold induction in relation to sham controls; that is, unity represents the absence of gene regulation. We averaged the abundances of proinflammatory marker genes (rows 2 through 9) in Table 2 for each particle type to obtain a mean score for a transcriptional proinflammatory response— “proinflammatory synopsis.” Ranking the particles in terms of the proinflammatory synopsis (Table 2) and PMN-based cellular lung inflammation (IEf in Table 1) shows good agreement and validates the relevance of our RNA expression data.
We gained insight into transcriptional regulations related to general stress response by examining the inducible 70-kDa heat shock gene Hsp1a1 as well as the metallothionein 1 and 2 genes (Mt1 and Mt2), all known to be up-regulated directly by oxidative stress and toxic chemicals—particularly heavy metals. Only PtxG particles showed a more than 2-fold increase in Hsp1a1 lung transcript levels 24 hr after instillation; for the other carbon black sample (Ptx90), mRNA levels were 3-fold decreased. Gene expression of Mt1 and Mt2 was increased for UfCP only; for DEP, these genes were 2-fold repressed. This indicates that, although the toxicity of metals may have contributed to the oxidative stress induced by UfCP and DEP, metals do not explain the extreme deviation of SootH from the linear response curve or the general trend in Figure 2B The expression analysis of 11 selected detoxification enzymes (Cyp1a1, Cyp1b1, Aldh3a1, Gclc, Gpx1, Gpx4, Gsr, Gsta1, Hmox1, Nqo1, and Ogg1) revealed that each particle type induced at least one of these genes. However, the only gene whose expression was induced specifically by SootH (3.9-fold up-regulated) and, to a lower extent, by DEP (1.6-fold up-regulated) was the phase I xenobiotic metabolizing enzyme Cyp1a1. To validate these data derived from pooled samples, we also quantified Cyp1a1 expression in SootH-instilled mice on the single-animal level (n = 4). Single-animal analysis confirmed our previous data detecting an induction of 4.0 ± 0.4 that is significantly (p = 0.001) different from sham controls [see Supplemental Material, Figure 2 (http://www.ehponline.org/members/2008/11370/suppl.pdf)]. Furthermore, low-OC particles (OC < 7%) were either not significantly affected (Ptx90, PtxG) or down-regulated (SootL, UfCP). In contrast to Cyp1a1, the closely related cytochrome 450 phase I enzyme isoform Cyp1b1 did not show regulation by more than 2-fold. The investigated phase II enzymes Gclc, Gpx1, Gpx4, and Gsr were more than 2-fold induced by UfCP, but none of them was more than 2-fold induced by the OC-rich DEP and SootH particles. 8-Oxoguanine DNA glycosylase (Ogg1), a DNA repair enzyme whose expression is associated with organics-related DNA adduct formation (Sorensen et al. 2003), is more than 2-fold induced by Ptx90 and UfCP and thus also is not a suitable marker for OC-rich particle instillation. In summary, our expression data identify Cyp1a1 as the only marker gene whose expression is specifically induced by OC-rich particle exposure. OC-rich soot particles induce expression of CYP1A1 protein in the lung Because the functional relevance of induced gene expression needs to be confirmed by a subsequent increase in expressed protein levels, we analyzed six of the investigated marker genes (Hmox1, Ptgs2, Cyp1a1, Gsta1, Hsp1a1, and Nqo1) on the protein level (HO1, COX2, CYP1A1, GSTYa1, HSP70, and NQO1) by immunoblotting of cytoplasmic extracts from lungs 24 hr after particle instillation (Figure 3
Immunohistologic localization of CYP1A expression Immunohistologic detection of CYP1A1 protein expression in lungs 24 hr after instillation of 20 μg particles revealed the strongest expression for SootH-exposed lungs (Figure 4
Discussion OxPot is a strong indicator for particle-induced inflammatory effects Several studies indicate that the OxPot of the particle surface is critical for biologic responses related to inflammation (Beck-Speier et al. 2005; Li et al. 2003b; Xia et al. 2006). Because for the six types of CDNPs investigated here the OxPot (based on a cell-free assay) can explain only about 80% of the observed variability in IEf (R2 = 0.77; Figure 2B Biotransformation of particle-adsorbed organics contributes to inflammatory effects The prime candidates for this additional mechanism are the enzymatic biotransformation of initially nontoxic (nonoxidizing) organic compounds into toxic derivatives and, to a lesser degree, the nonenzymatic, catalyst-mediated formation of free radicals such as hydroxyl radicals via Fenton chemistry by, for example, transition metals. The latter would not necessarily require a metabolic active cell, and the corresponding OxPot would probably be detected by our ascorbate-PCL–based OxPot measurement. However, the fact that metal-inducible Mt1 and Mt2 genes (Adams et al. 2002) were not up-regulated by DEP and SootH (Table 2) suggests no metal involvement. On the other hand, the induced expression of both the Cyp1a1 gene and CYP1A1 protein for SootH (3.9- and 21-fold for gene and protein, respectively) and, to a much lesser degree, for DEP (1.6-fold for both gene and protein) indicates that metabolic detoxification of organics takes place for particles with high OC. In addition, PtxG, the particle type with the lowest OC (1%), also shows a small induction (1.2- and 1.4-fold for gene and protein, respectively). All other low-OC particles show a down-regulation in both the Cyp1a1 gene and CYP1A1 protein. Hence, it is obviously not only the amount of organics, but also the type of organics, that determines the regulation of Cyp1a1. Pulmonary expression of Cyp1a1 has previously been identified as a possible bio-marker of exposure to DEPs in vitro and in vivo (Bonvallot et al. 2001; Takano et al. 2002). For instance, Takano et al. (2002) instilled DEP from a light-duty automobile source and observed Cyp1a1 transcript levels to be about 5-fold induced 24 hr after instillation of 50 μg DEP per mouse, whereas no effect was detected for 10 μg. (Bonvallot et al. 2001, Takano et al. 2002). This is consistent with results from our present study, in which instillation of 20 μg DEP from a heavy-duty diesel engine (SRM 1650a) mildly induced the Cyp1a1 expression on RNA and protein level (1.6-fold). Two main families of organic compounds that are known to be adsorbed onto ambient CDNPs are PAHs and quinones (Health Effects Institute 2002). After cellular uptake, PAHs could be desorbed from the CDNPs, become bioavailable to bind to the cytosolic aryl hydrocarbon receptor (AHR) and thereby induce target gene expression such as that of phase I metabolizing cytochrome P450 enzymes. The toxicity of many PAHs is known to depend on their bioactivation by P450 enzymes (Ramadoss et al. 2005). The hypothesis of PAH-related bioactivation of toxic compounds for SootH and DEP (as well as for PtxG) is supported by the chemical analysis of the particles. Both liquid chromatography and thermoanalytical investigation have revealed significant amounts of PAHs for SootH (~ 1%), exceeding those from SootL by a factor of about 50 (Schroeppel et al. 2003). Moreover, detailed chemical speciation reveals the presence of aromatic compounds such as benz(a)anthracene, benzo(k) fluoranthene, and/or benzo(a)pyrene, in significant amounts only on SootH, DEP, and PtxG samples (Matuschek et al. 2007; NIST 2000), which have been described as potent inducers of Cyp1a1 (Till et al. 1999). Mechanistic considerations PAH metabolism by Cyp1a1 produces reactive electrophilic metabolites, including ROS (Baulig et al. 2003; Martignoni et al. 2006). In the present study, we did not directly quantify ROS formation in the lungs of instilled mice, but we quantified several proinflammatory genes that are known to be regulated by redox-sensitive transcription factors such as NF-kB and AP-1 (Cho et al. 2006; Rahman et al. 2006). In vivo we found the lung transcripts for the cytokines Csf2, Cxcl1, Cxcl5, and Il6—all known to be largely regulated by NF-kB and AP-1 (reviewed by Castranova 2004)—to be induced by SootH and SootL instillation at a similar level (Table 2), whereas the in vitro OxPot of SootL exceeded that of SootH by a factor of about 6 (Figure 2B Interestingly, compared with sham controls, mice instilled with SootL and UfCP had Cyp1a1 expression that was about 3-fold down-regulated; these are the two particle types with the highest innate OxPot, and the very same particles caused the strongest expression of the proinflammatory mediators (Cxcl1, Cxcl5, and Il6), which are regulated by redox-sensitive transcription factors. Hence, the transcriptional repression of Cyp1a1 might be explained by inhibition of Cyp1a1 RNA expression by oxidative stress in general. This interpretation is consistent with the autoregulatory mechanism described by Morel et al. (1999) in a human hepatoma cell line; they found that intracellular ROS production disturbs the AHR-dependent induction of Cyp1a1 expression, which represents a protective negative feedback loop. Alternatively, Gharavi and El-Kadi (2005) showed in murine hepatoma cell lines that Cyp1a1 is down-regulated by the proinflammatory cytokines interleukin 1β (Il-1β), IL-6, and tumor necrosis factor α in an AHR-dependent manner. Even though both models address the liver and not the lung as studied here, this autoregulatory, ROS-protective mechanism could explain our observation that CDNPs with high innate OxPot induce significant down-regulation of Cyp1a1 expression. Cyp1a1 and Cyp1b1, two closely related and essential extrahepatic phase I P450 monooxygenases, are highly inducible in the human lung by certain aromatic compounds, such as benzo(a)pyrene, via AHR signaling (reviewed by Martignoni et al. 2006). However, with our instillation approach we observed no dependence of Cyp1b1 mRNA expression on organic compounds, because expression levels relative to controls were weakly induced by SootH to an expression level that is identical to that of SootL (1.4-fold). This apparent contradiction to the high expression of Cyp1a1 by SootH can be resolved if one considers that despite their close functional relationship, the CYP1A1 and CYP1B1 isoforms are regulated in a different manner. For example, Cyp1a1 transcript expression is repressed by proinflammatory cytokines (Gharavi and El-Kadi 2005), whereas Cyp1b1 expression is induced (Piscaglia et al. 1999). In this context, cAMP response elements as well as AP-1 sites—both frequently involved in proinflammatory signaling—have been identified in the murine Cyp1b1 but not Cyp1a1 promoter (Zheng and Jefcoate 2005). In summary, our results support the following mechanistic scheme (Figure 5
Quantitative model for IEf The analysis presented here can be used to derive a simple, quantitative model for predicting the in vivo toxicity of CDNPs based on a simple in vitro assay for OxPot and (in vivo) Cyp1a1 gene or protein expression. As a first approach, we performed a linear regression (forced through the origin) with the ascorbate-based in vitro test (OxPot) as independent and IEf as dependent parameters to obtain
As a second approach, we modeled the in vivo IEf as linear function of both OxPot and Cyp1a1 gene expression (GECyp1a1 expressed as fold induction after instillation of 20 μg particles), yielding
where we set GECyp1a1 to unity (no contribution from pathway 2), if Cyp1a1 was down-regulated (< 1-fold). As shown in Figure 6A
Because we derived our expression data from in vivo experiments, this model for toxicity prediction still requires animal exposures, although at a reduced amount. However, if future research will provide a means of obtaining Cyp1a1 expression data from the exposure of cell lines, the nanotoxicologic model we present here may provide a true alternative to animal exposures. Footnotes Supplemental Material is available online at http://www.ehponline.org/members/2008/11370/suppl.pdf This work was funded by grant HL 70542 from the National Institutes of Health and by FE-76177 from the German National Genome Network. References
|
PubMed related articles
Your browsing activity is empty. Activity recording is turned off. |
|||||||||||||||||||||||
Exp Toxicol Pathol. 2005 Jul; 57 Suppl 1():147-53.
[Exp Toxicol Pathol. 2005]J Aerosol Med. 2004 Summer; 17(2):140-52.
[J Aerosol Med. 2004]Environ Health Perspect. 2005 Jul; 113(7):823-39.
[Environ Health Perspect. 2005]Clin Immunol. 2003 Dec; 109(3):250-65.
[Clin Immunol. 2003]Mutat Res. 2005 Dec 30; 592(1-2):119-37.
[Mutat Res. 2005]Environ Health Perspect. 2005 Jul; 113(7):823-39.
[Environ Health Perspect. 2005]Cell Biol Toxicol. 1999; 15(6):375-80.
[Cell Biol Toxicol. 1999]J Air Waste Manag Assoc. 2000 Nov; 50(11):1897-903.
[J Air Waste Manag Assoc. 2000]Inhal Toxicol. 2003 Jan; 15(1):39-52.
[Inhal Toxicol. 2003]Part Fibre Toxicol. 2005 Oct 21; 2():10.
[Part Fibre Toxicol. 2005]Environ Health Perspect. 2006 Mar; 114(3):328-33.
[Environ Health Perspect. 2006]Environ Health Perspect. 2007 Feb; 115(2):187-94.
[Environ Health Perspect. 2007]Environ Health Perspect. 2006 Mar; 114(3):328-33.
[Environ Health Perspect. 2006]Environ Health Perspect. 2006 Mar; 114(3):328-33.
[Environ Health Perspect. 2006]Environ Sci Technol. 2007 Dec 15; 41(24):8406-11.
[Environ Sci Technol. 2007]Methods Enzymol. 1999; 300():437-56.
[Methods Enzymol. 1999]Environ Health Perspect. 2006 Mar; 114(3):328-33.
[Environ Health Perspect. 2006]Environ Health Perspect. 2006 Mar; 114(3):328-33.
[Environ Health Perspect. 2006]Mutat Res. 2003 Nov; 544(2-3):255-71.
[Mutat Res. 2003]Free Radic Biol Med. 2005 Apr 15; 38(8):1080-92.
[Free Radic Biol Med. 2005]Environ Health Perspect. 2003 Apr; 111(4):455-60.
[Environ Health Perspect. 2003]Nano Lett. 2006 Aug; 6(8):1794-807.
[Nano Lett. 2006]Environ Health Perspect. 2002 Oct; 110 Suppl 5():813-7.
[Environ Health Perspect. 2002]Am J Respir Cell Mol Biol. 2001 Oct; 25(4):515-21.
[Am J Respir Cell Mol Biol. 2001]Arch Toxicol. 2002 Apr; 76(3):146-51.
[Arch Toxicol. 2002]Expert Opin Drug Metab Toxicol. 2005 Jun; 1(1):9-21.
[Expert Opin Drug Metab Toxicol. 2005]Environ Sci Technol. 2007 Dec 15; 41(24):8406-11.
[Environ Sci Technol. 2007]Chem Biol Interact. 1999 Jan 29; 117(2):135-50.
[Chem Biol Interact. 1999]Am J Physiol Lung Cell Mol Physiol. 2003 Sep; 285(3):L671-9.
[Am J Physiol Lung Cell Mol Physiol. 2003]Expert Opin Drug Metab Toxicol. 2006 Dec; 2(6):875-94.
[Expert Opin Drug Metab Toxicol. 2006]Antioxid Redox Signal. 2006 Jan-Feb; 8(1-2):76-87.
[Antioxid Redox Signal. 2006]Antioxid Redox Signal. 2006 Mar-Apr; 8(3-4):681-9.
[Antioxid Redox Signal. 2006]Free Radic Biol Med. 2004 Oct 1; 37(7):916-25.
[Free Radic Biol Med. 2004]Mol Cell Biol. 1999 Oct; 19(10):6825-32.
[Mol Cell Biol. 1999]J Pharm Sci. 2005 Mar; 94(3):493-506.
[J Pharm Sci. 2005]Expert Opin Drug Metab Toxicol. 2006 Dec; 2(6):875-94.
[Expert Opin Drug Metab Toxicol. 2006]J Pharm Sci. 2005 Mar; 94(3):493-506.
[J Pharm Sci. 2005]Biochem Pharmacol. 1999 Jul 1; 58(1):157-65.
[Biochem Pharmacol. 1999]Mol Pharmacol. 2005 Feb; 67(2):499-512.
[Mol Pharmacol. 2005]Biochem Pharmacol. 2007 Jun 15; 73(12):1853-62.
[Biochem Pharmacol. 2007]Environ Health Perspect. 2006 Mar; 114(3):328-33.
[Environ Health Perspect. 2006]Res Rep Health Eff Inst. 2004 Dec; (126):1-47; discussion 49-63.
[Res Rep Health Eff Inst. 2004]Environ Sci Technol. 2007 Dec 15; 41(24):8406-11.
[Environ Sci Technol. 2007]